Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00511849 · ClinicalTrials.gov registry record · Phase 1

Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors

A Phase 1 study of Neoplasms, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
43
Enrollment target
4
Study locations

NCT00511849 is a Phase 1 study of Neoplasms that has completed, run by Pfizer. The registered enrollment target is 43 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00511849, a Phase 1 study of Neoplasms, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
43 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to test SU011248 (sunitinib) in combination with paclitaxel/carboplatin. This combination regimen will be tested for safety and antitumor activity.

Conditions Studied

Neoplasms

Interventions

  • DRUG carboplatin + SU011248 (sunitinib) + paclitaxel

Study Locations (4)

Michigan

  • Pfizer Investigational Site - Detroit

Pennsylvania

  • Pfizer Investigational Site - Philadelphia

Texas

  • Pfizer Investigational Site - Houston

Wisconsin

  • Pfizer Investigational Site - Madison

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2005-11
Est. Completion 2009-02
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00511849

The ClinicalTrials.gov registry entry for NCT00511849 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which carboplatin + SU011248 (sunitinib) + paclitaxel is the first listed.

NCT00511849 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Michigan, Pennsylvania, Texas.

Frequently Asked Questions

What is clinical trial NCT00511849 about?

NCT00511849 is a clinical study titled "Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors". The purpose of this study is to test SU011248 (sunitinib) in combination with paclitaxel/carboplatin. This combination regimen will be tested for safety and antitumor activity.

What is the current status of trial NCT00511849?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2005-11. Estimated completion is 2009-02.

What conditions does trial NCT00511849 study?

This clinical trial studies the following conditions: Neoplasms.

What interventions are being tested in trial NCT00511849?

The interventions under investigation include: carboplatin + SU011248 (sunitinib) + paclitaxel (DRUG).

Who is sponsoring clinical trial NCT00511849?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00511849 being conducted?

This trial has 4 study locations across Michigan, Pennsylvania, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasms

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.